Briefs and Reports
Saving a trillion dollars with a universal coronavirus vaccine
What if we had a vaccine that protected against all major illness-causing coronaviruses? An Advanced Market Commitment to Incentivize a Universal Coronavirus Vaccine Before the Next Variant explains how few billion dollars in the form of an advanced market commitment could stimulate the development of such a vaccine. Just counting averted deaths alone, it could be worth $1.08 trillion in value.
Air Safety to Combat Global Catastrophic Biorisk
One day, humanity may look back on things like flu like you and I look at cholera today: the unpleasant but inevitable outcome of a failure to clean things properly. Like we use chlorine to clean our water, we may end up using far-UV light, proper filtration, and ventilation to rid the air of contamination on a massive scale. Air Safety to Combat Global Catastrophic Biorisk, a collaborative effort between 1Day Sooner and Rethink Priorities, outlines the next steps to get there.
Exploring the risks of human challenge trials for COVID-19
We introduce an interactive model for exploring some risks of a SARS-COV-2 dosing study, a prerequisite for any COVID-19 challenge trials. Read the full paper here.
COVID-19 CHALLENGE TRIAL RISK MODEL
Long-Term Risks of COVID-19
COVID-19 reinfection summary
UNIVERSAL FLU VACCINE
1Day Sooner’s report reviews current and proposed efforts for a universal influenza vaccine, and provides some background information on influenza relevant to universal vaccine development through human challenge trials. It does not attempt a comprehensive overview of the field of influenza vaccine development— those interested in an in-depth approach are encouraged to look at NIAD’s roadmap for universal influenza vaccine development. We also provide a resource repository of relevant literature.
Treatments for COVID-19
- Convalescent Plasma
- Interferon Beta (SNG001)
- Monoclonal Antibodies
Ethical Considerations for Challenge Trials
Informed consent forms the cornerstone of contemporary medical ethics. A COVID-19 human challenge trial imposes unusual burdens and risks on healthy participants. It is therefore critical that research personnel create a robust screening and informed consent process to ensure participants do not find themselves subject to burdens and risks to which they might not have otherwise consented.
This report attempts to identify, evaluate and address barriers to genuine informed consent that arise in this novel context at various stages in the informed consent process. These stages include: selection of participants, training of personnel, screening, providing information, giving of consent, and ongoing consent until the end of the study.